Literature DB >> 26826720

Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group.

Sun Hyun Bae1, Mi-Sook Kim2, Won Il Jang3, Chul-Seung Kay4, Woochul Kim5, Eun Seog Kim6, Jin Ho Kim7, Jin Hee Kim8, Kwang Mo Yang9, Kyu Chan Lee10, A Ram Chang11, Sunmi Jo12.   

Abstract

OBJECTIVE: To investigate practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea.
METHODS: In June 2013, the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology conducted a national patterns-of-care survey about stereotactic body radiotherapy to the liver lesion in hepatocellular carcinoma, consisting of 19 questions and 2 clinical scenarios.
RESULTS: All 208 radiation oncologists (100%), who are regular members of Korean Society for Radiation Oncology, responded to this survey. Among these, 95 radiation oncologists were specialists for hepatology; 64 physicians did not use stereotactic body radiotherapy for hepatocellular carcinoma, and 31 physicians used stereotactic body radiotherapy. Most physicians (52%) performed stereotactic body radiotherapy to hepatocellular carcinoma in ≤5 cases per year. Physicians applied stereotactic body radiotherapy according to tumour size and baseline Child-Pugh class. All physicians agreed the use of stereotactic body radiotherapy to 2.8-cm hepatocellular carcinoma with Child-Pugh class of A, while 23 physicians (74%) selected stereotactic body radiotherapy for Child-Pugh class of B. Nineteen physicians (61%) selected stereotactic body radiotherapy to 5-cm hepatocellular carcinoma with Child-Pugh class of A, and only 14 physicians (45%) selected stereotactic body radiotherapy for Child-Pugh class of B. On the other hand, the preferred dose scheme was same as 60 Gy in three fractions.
CONCLUSIONS: Among radiation oncologists in Korea, there was diversity in the practice for stereotactic body radiotherapy to the liver lesion in hepatocellular carcinoma. Additional prospective studies are necessary to standardize the practice and establish Korea-specific practice guidelines for hepatocellular carcinoma stereotactic body radiotherapy.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Korea; hepatocellular carcinoma; stereotactic body radiotherapy; survey

Mesh:

Year:  2016        PMID: 26826720      PMCID: PMC4886133          DOI: 10.1093/jjco/hyv209

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  24 in total

1.  The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy.

Authors:  A Sahgal; D Roberge; D Schellenberg; T G Purdie; A Swaminath; J Pantarotto; E Filion; Z Gabos; J Butler; D Letourneau; G L Masucci; L Mulroy; A Bezjak; L A Dawson; M Parliament
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-05-24       Impact factor: 4.126

2.  American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy.

Authors:  Louis Potters; Michael Steinberg; Christopher Rose; Robert Timmerman; Samuel Ryu; James M Hevezi; James Welsh; Minesh Mehta; David A Larson; Nora A Janjan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-15       Impact factor: 7.038

3.  A survey of stereotactic body radiotherapy use in the United States.

Authors:  Hubert Pan; Daniel R Simpson; Loren K Mell; Arno J Mundt; Joshua D Lawson
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

4.  Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study.

Authors:  Alejandra Méndez Romero; Wouter Wunderink; Shahid M Hussain; Jacco A De Pooter; Ben J M Heijmen; Peter C J M Nowak; Joost J Nuyttens; Rene P Brandwijk; Cees Verhoef; Jan N M Ijzermans; Peter C Levendag
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

5.  Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group.

Authors:  Yasushi Nagata; Masahiro Hiraoka; Takashi Mizowaki; Yuichiro Narita; Yukinori Matsuo; Yoshiki Norihisa; Hiroshi Onishi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-01       Impact factor: 7.038

6.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

Review 7.  Role of stereotactic body radiation therapy for hepatocellular carcinoma.

Authors:  Naoko Sanuki; Atsuya Takeda; Etsuo Kunieda
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

8.  A Survey of Stereotactic Body Radiotherapy in Korea.

Authors:  Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul-Seung Kay; Woochul Kim; Eun Seog Kim; Jin Ho Kim; Jin Hee Kim; Kwang Mo Yang; Kyu Chan Lee; A Ram Chang; Sunmi Jo
Journal:  Cancer Res Treat       Date:  2014-11-24       Impact factor: 4.679

Review 9.  Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy.

Authors:  Jimm Grimm; Tamara LaCouture; Raymond Croce; Inhwan Yeo; Yunping Zhu; Jinyu Xue
Journal:  J Appl Clin Med Phys       Date:  2011-02-08       Impact factor: 2.243

10.  High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.

Authors:  Won Il Jang; Mi-Sook Kim; Sun Hyun Bae; Chul Koo Cho; Hyung Jun Yoo; Young Seok Seo; Jin-Kyu Kang; So Young Kim; Dong Han Lee; Chul Ju Han; Jin Kim; Su Cheol Park; Sang Bum Kim; Eung-Ho Cho; Young Han Kim
Journal:  Radiat Oncol       Date:  2013-10-27       Impact factor: 3.481

View more
  3 in total

Review 1.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

2.  Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05).

Authors:  Sun Hyun Bae; Hee Chul Park; Won Sup Yoon; Sang Min Yoon; In-Hye Jung; Ik Jae Lee; Jun Won Kim; Jinsil Seong; Tae Hyun Kim; Taek-Keun Nam; Youngmin Choi; Sun Young Lee; Hong Seok Jang; Dong Soo Lee; Jin Hee Kim
Journal:  Cancer Res Treat       Date:  2019-04-10       Impact factor: 4.679

3.  Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival.

Authors:  Jared R Robbins; Ryan K Schmid; Abdulrahman Y Hammad; Thomas Clark Gamblin; Beth A Erickson
Journal:  Cancer Med       Date:  2019-01-31       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.